On Invalid Date, Merrimack Pharmaceuticals (NASDAQ: MACK) reported Q4 2023 earnings per share (EPS) of -$0.01, up 66.67% year over year. Total Merrimack Pharmaceuticals earnings for the quarter were -$240.00 thousand. In the same quarter last year, Merrimack Pharmaceuticals's earnings per share (EPS) was -$0.03.
As of Q2 2024, Merrimack Pharmaceuticals's earnings has grown year over year. Merrimack Pharmaceuticals's earnings in the past year totalled -$1.18 million.
What is MACK's earnings date?
Merrimack Pharmaceuticals's earnings date is Invalid Date. Add MACK to your watchlist to be reminded of MACK's next earnings announcement.
What was MACK's revenue last quarter?
On Invalid Date, Merrimack Pharmaceuticals (NASDAQ: MACK) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Merrimack Pharmaceuticals's revenue was $0.00.
What was MACK's revenue growth in the past year?
As of Q2 2024, Merrimack Pharmaceuticals's revenue has grown null year over year. Merrimack Pharmaceuticals's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.